Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 15/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131914 | 0.79 | ERN1 (0.41) | AKR1C3AKR1C2CETPERN1NR1I2 | |
| SCHEMBL132467 | 0.74 | CETP (0.53) | CETPNR1I2CASR | |
| SCHEMBL4540699 | 0.74 | MAOB (0.48) | ERN1 | |
| SCHEMBL8940819 | 0.73 | HDAC4 (0.50) | CETPERN1HDAC4HDAC8CASR | |
| SCHEMBL2662354 | 0.72 | AKR1C3 (0.46) | AKR1C3AKR1C2CETPHDAC4HDAC8 | |
| SCHEMBL31058019 | 0.72 | ERN1 (0.47) | AKR1C3AKR1C2ERN1HDAC4HDAC8 | |
| SCHEMBL132850 | 0.72 | CETP (0.43) | AKR1C3AKR1C2CETPNR1I2CASR | |
| SCHEMBL130261 | 0.72 | CETP (0.41) | AKR1C3AKR1C2CETPNR1I2CASR | |
| SCHEMBL29786750 | 0.71 | CETP (0.49) | AKR1C3AKR1C2CETPNR1I2 | |
| SCHEMBL16697835 | 0.71 | ALDH1A1 (0.50) | AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | APOB, LDLR, CETP | AKR1C3 3225/4885AKR1C2 2704/4885CETP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.